Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Current Assets (2016 - 2025)

Perspective Therapeutics' Current Assets history spans 15 years, with the latest figure at $178.5 million for Q3 2025.

  • For Q3 2025, Current Assets fell 33.93% year-over-year to $178.5 million; the TTM value through Sep 2025 reached $178.5 million, down 33.93%, while the annual FY2024 figure was $231.2 million, 1272.93% up from the prior year.
  • Current Assets for Q3 2025 was $178.5 million at Perspective Therapeutics, down from $196.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $294.2 million in Q2 2024 and bottomed at $16.8 million in Q4 2023.
  • The 5-year median for Current Assets is $65.0 million (2021), against an average of $114.8 million.
  • The largest annual shift saw Current Assets crashed 68.36% in 2023 before it skyrocketed 1272.93% in 2024.
  • A 5-year view of Current Assets shows it stood at $63.6 million in 2021, then dropped by 16.33% to $53.2 million in 2022, then crashed by 68.36% to $16.8 million in 2023, then surged by 1272.93% to $231.2 million in 2024, then fell by 22.78% to $178.5 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Current Assets are $178.5 million (Q3 2025), $196.0 million (Q2 2025), and $215.7 million (Q1 2025).